New insights for IL-6 targeted therapy as an adjuvant treatment for non-small-cell lung cancer

Therapeutic Delivery

Volumn 4, Issue 10, 2013, Pages 1221-1223

  Zarogoulidis, Paul ^a,b   Yarmus, Lonny ^c   Zarogoulidis, Konstantinos ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

IL 6; molecular pathway; NSCLC; SCLC; transformation

Indexed keywords

EID: 84885594973     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.13.95     Document Type: Review

References (25)

1. Koh E, Iizasa T, Yamaji H et al. Significance of the correlation between the expression of interleukin 6 and clinical features in patients with non-small cell lung cancer. Int. J. Surg. Pathol. 20(3), 233-239 (2012).
2. Pine SR, Mechanic LE, Enewold L et al. Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. J. Natl Cancer Inst. 103(14), 1112-1122 (2011).
3. Chang CH, Hsiao CF, Yeh YM et al. Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy. Int. J. Cancer 132(9), 1977-1985 (2013).
4. Lengacher CA, Kip KE, Barta M et al. A pilot study evaluating the effect of mindfulness-based stress reduction on psychological status, physical status, salivary cortisol, and interleukin-6 among advanced-stage cancer patients and their caregivers. J. Holist. Nurs. 30(3), 170-185 (2012).
5. Kita H, Shiraishi Y, Watanabe K et al. Does postoperative serum interleukin-6 influence early recurrence after curative pulmonary resection of lung cancer? Ann. Thorac. Cardiovasc. Surg. 17(5), 454-460 (2011).
6. Ishiguro Y, Ishiguro H, Miyamoto H. Epidermal growth factor receptor tyrosine kinase inhibition up-regulates interleukin-6 in cancer cells and induces subsequent development of interstitial pneumonia. Oncotarget 4(4), 550-559 (2013).
7. Gao SP, Mark KG, Leslie K et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J. Clin. Invest. 117(12), 3846-3856 (2007).
8. Hingorani AD, Casas JP. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet 379(9822), 1214-1224 (2012).
9. Mizuhashi S, Nakamura K, Mori Y, Noda M, Nakanishi K. Insulin allergy and immunologic insulin resistance caused by interleukin-6 in a patient with lung cancer. Diabetes Care 29(7), 1711-1712 (2006).
10. Osterlund P, Orpana A, Elomaa I, Repo H, Joensuu H. Raltitrexed treatment promotes systemic inflammatory reaction in patients with colorectal carcinoma. Br. J. Cancer 87(6), 591-599 (2002).
11. Song L, Rawal B, Nemeth JA, Haura EB. JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling. Mol. Cancer Ther. 10(3), 481-494 (2011).
12. Yi H, Cho HJ, Cho SM et al. Blockade of interleukin-6 receptor suppresses the proliferation of H460 lung cancer stem cells. Int. J. Oncol. 41(1), 310-316 (2012).
13. Oldford SA, Haidl ID, Howatt MA, Leiva CA, Johnston B, Marshall JS. A critical role for mast cells and mast cell-derived IL-6 in TLR2-mediated inhibition of tumor growth. J. Immunol. 185(11), 7067-7076 (2010).
14. Chen KH, Hsu WM, Wu CC. Increased interleukin-6 in aqueous humor of a patient with lung-metastatic intraocular adenocarcinoma. Am. J. Ophthalmol. 135(2), 237-239 (2003).
15. Wang YC, Xu GL, Jia WD et al. Estrogen suppresses metastasis in rat hepatocellular carcinoma through decreasing interleukin-6 and hepatocyte growth factor expression. Inflammation 35(1), 143-149 (2012).
16. Wang Y, Yu C, Pan Y et al. A novel synthetic mono-carbonyl analogue of curcumin, A13, exhibits anti-inflammatory effects in vivo by inhibition of inflammatory mediators. Inflammation 35(2), 594-604 (2012).
17. Wu DW, Tsai LH, Chen PM et al. Loss of TIMP-3 promotes tumor invasion via elevated IL-6 production and predicts poor survival and relapse in HPV-infected non-small cell lung cancer. Am. J. Pathol. 181(5), 1796-1806 (2012).
18. Kim SH, Lee JE, Yang SH, Lee SW. Induction of cytokines and growth factors by rapamycin in the microenvironment of brain metastases of lung cancer. Oncol. Lett. 5(3), 953-958 (2013).
19. O'Donoghue RJ, Knight DA, Richards CD et al. Genetic partitioning of interleukin-6 signalling in mice dissociates Stat3 from Smad3-mediated lung fibrosis. EMBO Mol. Med. 4(9), 939-951 (2012).
20. Ando K, Takahashi F, Motojima S et al. Possible role for tocilizumab, an anti-interleukin-6 receptor antibody, in treating cancer cachexia. J. Clin. Oncol. 31(6), e69-e72 (2013).
21. Li J, Hu XF, Xing PX. CNTO-328 (Centocor). Curr. Opin. Investig. Drugs 6(6), 639-645 (2005).
22. Dorff TB, Goldman B, Pinski JK et al. Clinical and correlative results of SWOG S0354: a Phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin. Cancer Res. 16(11), 3028-3034 (2010).
23. Silverman J, Liu Q, Bakker A et al. Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains. Nat. Biotechnol. 23(12), 1556-1561 (2005).
24. Righi L, Volante M, Rapa I, Scagliotti GV, Papotti M. Neuro-endocrine tumours of the lung. A review of relevant pathological and molecular data. Virchows Arch. 451(Suppl. 1), S51-S59 (2007).
25. Chang KT, Tsai CM, Chiou YC, Chiu CH, Jeng KS, Huang CY. IL-6 induces neuroendocrine dedifferentiation and cell proliferation in non-small cell lung cancer cells. Am. J. Physiol. Lung Cell Mol. Physiol. 289(3), L446-L453 (2005).